Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TR), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TR for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Viking Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CONFERENCE CALL SCHEDULED FOR 4:30 P.M. ET TODAY PHASE 3 VANQUISH REGISTRATION TRIALS UNDERWAY FOR VK2735 IN OBESITY PHASE 2 VENTURE-ORAL DOSING TRIAL ENROLLMENT COMPLETED; TOP-LINE RESULTS EXPECTED 2H25 CONTINUED PROGRESS WITH AMYLIN PROGRAM; IND PLANNED 4Q25 STRONG QUARTER-END CASH POSITION OF $808 MILLION SAN DIEGO , JULY 23, 2025 /PRNEWSWIRE/ -- VIKING THERAPEUTICS, INC. ("VIKING") (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE SECOND QUARTER AND SIX MONTHS ENDED JUNE 30, 2025, AND PROVIDED AN UPDATE ON ITS CLINICAL PIPELINE AND OTHER CORPORATE DEVELOPMENTS.

VIKING THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

CONFERENCE CALL SCHEDULED FOR WEDNESDAY, JULY 23 AT 4:30 P.M. EASTERN TIME   SAN DIEGO , JULY 16, 2025 /PRNEWSWIRE/ -- VIKING THERAPEUTICS, INC. ("VIKING") (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, TODAY ANNOUNCED THAT THE COMPANY WILL RELEASE FINANCIAL RESULTS FOR THE SECOND QUARTER 2025 AFTER THE MARKET CLOSE ON WEDNESDAY, JULY 23, 2025.

VIKING THERAPEUTICS TO REPORT FINANCIAL RESULTS FOR SECOND QUARTER 2025 ON JULY 23, 2025

VANQUISH-1 AND VANQUISH-2 STUDIES TO EVALUATE SUBCUTANEOUS VK2735 IN OBESE ADULTS WITH AND WITHOUT TYPE 2 DIABETES SAN DIEGO , JUNE 25, 2025 /PRNEWSWIRE/ -- VIKING THERAPEUTICS, INC. (VIKING) (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, TODAY ANNOUNCED THE INITIATION OF THE VANQUISH PHASE 3 CLINICAL PROGRAM FOR VK2735, THE COMPANY'S DUAL AGONIST OF THE GLUCAGON-LIKE PEPTIDE 1 (GLP-1) AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) RECEPTORS. VK2375 IS BEING DEVELOPED IN BOTH ORAL AND SUBCUTANEOUS FORMULATIONS FOR THE POTENTIAL TREATMENT OF METABOLIC DISORDERS SUCH AS OBESITY.

VIKING THERAPEUTICS ANNOUNCES INITIATION OF PHASE 3 OBESITY CLINICAL PROGRAM WITH GLP-1/GIP AGONIST VK2735

CONFERENCE CALL SCHEDULED FOR 4:30 P.M. ET TODAY PHASE 3 TRIALS FOR SUBCUTANEOUS VK2735 EXPECTED TO BEGIN 2Q25 PHASE 2 VENTURE-ORAL DOSING TRIAL IN OBESITY FULLY ENROLLED; DATA EXPECTED 2H25 BROAD MANUFACTURING AGREEMENT WITH CORDENPHARMA TO SUPPORT FUTURE COMMERCIALIZATION OF VK2735 STRONG QUARTER-END CASH POSITION OF $852 MILLION SAN DIEGO , APRIL 23, 2025 /PRNEWSWIRE/ --VIKING THERAPEUTICS, INC. ("VIKING") (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025, AND PROVIDED AN UPDATE ON ITS CLINICAL PIPELINE AND OTHER CORPORATE DEVELOPMENTS.

VIKING THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

13-WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF ORAL VK2735 DOSED ONCE DAILY RESULTS EXPECTED IN 2H25 SAN DIEGO , MARCH 26, 2025 /PRNEWSWIRE/ --VIKING THERAPEUTICS, INC. ("VIKING") (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, TODAY ANNOUNCED THE COMPLETION OF SUBJECT ENROLLMENT IN ITS PHASE 2 CLINICAL TRIAL OF THE ORAL TABLET FORMULATION OF VK2735, THE COMPANY'S DUAL AGONIST OF THE GLUCAGON-LIKE PEPTIDE 1 (GLP-1) AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) RECEPTORS. VK2375 IS BEING DEVELOPED IN BOTH ORAL AND SUBCUTANEOUS FORMULATIONS FOR THE POTENTIAL TREATMENT OF VARIOUS METABOLIC DISORDERS SUCH AS OBESITY.

VIKING THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 2 VENTURE-ORAL DOSING TRIAL OF VK2735 TABLET FORMULATION IN PATIENTS WITH OBESITY

LONG-TERM AGREEMENT SECURES DEDICATED CAPACITY FOR MULTI-TON ANNUAL SUPPLY OF VK2735 ACTIVE PHARMACEUTICAL INGREDIENT SECURES DEDICATED FILL/FINISH CAPACITY FOR 100 MILLION ANNUAL AUTOINJECTOR SUPPLY AND ADDITIONAL 100 MILLION ANNUAL VIAL/SYRINGE SUPPLY PROVIDES ANNUAL CAPACITY OF OVER 1 BILLION ORAL TABLETS VIKING TO MAKE PREPAYMENTS TOTALING $150 MILLION BETWEEN 2025-2028 SAN DIEGO , MARCH 11, 2025 /PRNEWSWIRE/ --VIKING THERAPEUTICS, INC. ("VIKING") (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, TODAY ANNOUNCED THAT IT HAS SIGNED A BROAD, MULTI-YEAR MANUFACTURING AGREEMENT WITH CORDENPHARMA, AN INDUSTRY-LEADING CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO), COVERING BOTH THE ACTIVE PHARMACEUTICAL INGREDIENT (API) AND FINAL FINISHED PRODUCT SUPPLY FOR ITS VK2735 PROGRAM FOR OBESITY. THE AGREEMENT PROVIDES VIKING WITH SUFFICIENT LONG-TERM SUPPLY OF BOTH SUBCUTANEOUS AND ORAL VK2735 PRODUCT FORMS TO SUPPORT A POTENTIAL MULTI-BILLION-DOLLAR ANNUAL PRODUCT OPPORTUNITY.

VIKING THERAPEUTICS SIGNS BROAD MANUFACTURING AGREEMENT WITH CORDENPHARMA TO SUPPORT COMMERCIALIZATION OF VK2735

SAN DIEGO , MARCH 4, 2025 /PRNEWSWIRE/ --VIKING THERAPEUTICS, INC. ("VIKING") (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, TODAYANNOUNCED THAT THE COMPANY WILL PARTICIPATE AT MULTIPLE UPCOMING INVESTOR CONFERENCES. DETAILS OF THE COMPANY'S PARTICIPATION ARE AS FOLLOWS: LEERINK PARTNERS GLOBAL HEALTHCARE CONFERENCE 2025 DETAILS: VIKING MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AND IN 1-ON-1 MEETINGSCONFERENCE DATE: MARCH 10-12, 2025 FIRESIDE CHAT TIMING: 9:20  9:50 A.M.

VIKING THERAPEUTICS TO PARTICIPATE AT UPCOMING INVESTOR CONFERENCES

CONFERENCE CALL SCHEDULED FOR 4:30 P.M. ET TODAY INITIATION OF PHASE 3 STUDIES FOR SUBCUTANEOUS VK2735 FOR OBESITY PLANNED FOR 2Q25 PHASE 2 VENTURE-ORAL DOSING TRIAL EVALUATING VK2735 IN OBESITY UNDERWAY STRONG YEAR-END CASH POSITION OF $903 MILLION SAN DIEGO , FEB. 5, 2025 /PRNEWSWIRE/ --VIKING THERAPEUTICS, INC. ("VIKING") (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2024, AND PROVIDED AN UPDATE ON ITS CLINICAL PIPELINE AND OTHER CORPORATE DEVELOPMENTS.

VIKING THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

CONFERENCE CALL SCHEDULED FOR WEDNESDAY, FEBRUARY 5 AT 4:30 P.M. EASTERN TIME SAN DIEGO , JAN. 29, 2025 /PRNEWSWIRE/ -- VIKING THERAPEUTICS, INC. ("VIKING") (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, TODAY ANNOUNCED THAT THE COMPANY WILL RELEASE FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR-END 2024 AFTER THE MARKET CLOSE ON WEDNESDAY, FEBRUARY 5, 2025.

VIKING THERAPEUTICS TO REPORT FINANCIAL RESULTS FOR FOURTH QUARTER AND YEAR-END 2024 ON FEBRUARY 5, 2025

13-WEEK STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL VK2735 DOSED ONCE DAILY SAN DIEGO , JAN. 8, 2025 /PRNEWSWIRE/ -- VIKING THERAPEUTICS, INC. ("VIKING") (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, TODAY ANNOUNCED THE INITIATION OF A PHASE 2 CLINICAL TRIAL OF THE ORAL TABLET FORMULATION OF VK2735, THE COMPANY'S DUAL AGONIST OF THE GLUCAGON-LIKE PEPTIDE 1 (GLP-1) AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) RECEPTORS. VK2375 IS BEING DEVELOPED IN BOTH ORAL AND SUBCUTANEOUS FORMULATIONS FOR THE POTENTIAL TREATMENT OF VARIOUS METABOLIC DISORDERS SUCH AS OBESITY.

Viking Therapeutics, Inc.

VKTX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Viking Therapeutics, Inc.

VKTX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

VKTX